Background: Rate control medications (RCM) for atrial fibrillation (AF) usually prescribed are diltiazem (DTZ) and beta blockers. Patients entering the Emergency Department (ED) with AF often convert to a normal sinus rhythm (NSR) by means of spontaneous conversion to normal sinus rhythm (SCNSR), electrical cardioversion, or medications. However, recurrent AF often leads to repeat ED visits and frequent hospitalizations within one year. Goals: To evaluate admission and discharge metoprolol (MTP) and DTZ doses for patients presenting to the ED with rapid AF. Methods: Retrospective, single center chart review of MTP and DTZ doses on admission and discharge for patients admitted with a primary diagnosis of AF. Patients who received new or an increase of other RCMs, or antiarrhythmic medications with RCM properties were excluded. Results: Of 402 patients, 310 (77%) had a heart rate ≥110 bpm on admission. Of those with a rapid rate, 235 (76%) converted to NSR after admission predominantly due to SCNSR. The mean daily dose of MTP was 61mg on admission and 65mg at discharge. The mean DTZ dose on admission was 188mg and 157mg at discharge. Discussion: The discharge doses of 65mg of MTP and 157mg of DTZ were well below the recommended doses of RCMs for AF. The RATAF trial demonstrated adequate rate and symptom control with MTP 100mg/day and DTZ up to 360mg/day. The current study demonstrated significant under dosing of RCMs to manage future rapid ventricular rate. It is possible patients with rapid ventricular rates who convert to NSR, which by itself, results in rate control, would not have attention by the provider focused on the rapid admission rate. Most patients who convert to NSR do not have the substrate leading to AF corrected. Thus, it is not surprising recurrence of AF, regardless of the method of cardioversion, occurs in approximately 70% of patients within one year. It is likely when AF recurs it will have the same rapid rate unless RCMs are increased before discharge from the first initial admission dose. It is possible at discharge an order set may lead to a more logical assessment of targeted RCMs. Lack of long term follow-up to address outcome of apparent under dosing of RCM is a limitation. Conclusion: This single center study found no significant increases in MTP and DTZ dosing at the time of discharge for patients with rapid AF who reverted to NSR after admission. It is possible that modification of RCMs before hospital discharge may decrease future ED admission for symptomatic AF.
Read full abstract